A Study of Abatacept in Participants That Only Recently Started to Develop Rheumatoid Arthritis (ASCEND)

Bristol-Myers Squibb (BMS)

Status: Completed

Conditions: Rheumatoid Arthritis

Study type: Observational

Funder types: Industry

Identifiers

NCT03457792

IM101-679

Details and patient eligibility

About

This is a long-term study of Abatacept in participants that only recently started to develop Rheumatoid Arthritis, a chronic inflammatory disorder affecting mainly joints.

Enrollment: 158 patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Participants recently (within the last 24 months before enrollment) diagnosed with established moderate to severe active RA
• Participants naïve of abatacept and who, at their physician's discretion, are initiated with abatacept according the German label/SmPC (Summary of product characteristics)

Exclusion criteria

• Participants who are currently included in any interventional clinical trial in RA

Other protocol defined inclusion/exclusion criteria could apply

Trial design

158 participants in 1 patient group

Abatacept for Rheumatoid Arthritis (RA)

Description:

Participants diagnosed with moderate to severe active RA within the last 24 months and initiated treatment with Abatacept